#ECTRIMS2021 – Ponvory Effective in Early MS in OPTIMUM Trial

#ECTRIMS2021 – Ponvory Effective in Early MS in OPTIMUM Trial

308949

#ECTRIMS2021 – Ponvory Effective in Early MS in OPTIMUM Trial

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Treatment with Ponvory (ponesimod) markedly reduces relapse rates, fatigue, and evidence of brain damage compared with Aubagio (teriflunomide), with its beneficial effects particularly pronounced in individuals with relatively early multiple sclerosis (MS), according to a new analysis of…

You must be logged in to read/download the full post.